Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective study of omalizumab in moderate to severe allergic asthma
ChiCTR2000029142Phase 4Recruiting
- Sponsor
- Beijing Institute of Respiratory Medicine
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of omalizumab in allergic asthma (2 arms), sponsored by Beijing Institute of Respiratory Medicine. Primary endpoint: Exacerbations. Started Jan 2020; status: recruiting.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on ChiCTR2000029142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029142.